List view / Grid view
29 April 2019 | By European Pharmaceutical Review
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
25 February 2019 | By European Pharmaceutical Review
Results of a phase III clinical trial suggest that dual antiplatelet therapy may improve outcomes for patients with established coronary artery disease (CAD) and type 2 diabetes....
2 January 2019 | By European Pharmaceutical Review
A study has found that when compared with other drugs, canagliflozin may not be associated with fractures in patients with diabetes...
2 November 2018 | By Iqra Farooq (European Pharmaceutical Review)
The Endocrine Society has reported that increasing costs of insulin means that people are often deciding to forgo necessary treatment...
4 October 2018 | By Iqra Farooq (European Pharmaceutical Review)
Lixisenatide has shown prevention of kidney damage in patients with type 2 diabetes or cardiovascular disease through a study by the EASD...
11 September 2018 | By Mike Stones
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
12 July 2018 | By European Pharmaceutical Review
Two companies will work closely together on future development, distribution, promotion, access, marketing and sales of Invokana (canagliflozin) for type 2 diabetes...
17 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Women who have gestational diabetes mellitus during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future...
11 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Scientists have developed an online interactive app to help motivate patients to be more active in managing their disease...
10 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Health Canada has approved Ozempic to improve glycemic control in adults with type 2 diabetes mellitus when metformin is not tolerated or contraindicated...
12 December 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes...
7 December 2017 | By European Pharmaceutical Review
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
23 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Bydureon BCise for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines...
17 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have identified that the drug semaglutide resulted in better glycemic control than placebo for patients with type 2 diabetes...
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
Follow: